Phase 4 Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Genotype IV Infected Egyptian Patients
Sponsor study identifier
Secondary identifiers
REGISTRY · NZEKRI
observational
100,000
1 country
1
Study Start
January 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Retrospective prospective cohort study aimed at Assessing the predictors to the response to the antiviral combined therapy with pegylated Interferon (Both types: Alfa 2 A and Alfa 2 B) in hepatitis C virus infected Egyptian patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2011
Date type not reportedThis date has not been verified as actual or estimated.
December 25, 2012
Actual (reported)January 1, 2013
Actual (reported)January 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Assess the response to the Interferon therapy.
After 72 weeks of the start of therapy of each patient
Predictors of response to therapy
at the end of the study
chronic hepatitis C virus , genotype IV, infected Egyptian patients
Viral Hepatitis Treatment Units affiliated to National Committee for Control of Viral Hepatitis
Cairo, Cairo Governorate, 002, Egypt
N Zekri AR, Raafat AM, Elmasry S, Bahnassy AA, Saad Y, Dabaon HA, El-Kassas M, Shousha HI, Nassar AA, El-Dosouky MA, Hussein N. Promotor methylation: does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? Ann Hepatol. 2014 Sep-Oct;13(5):518-24.
Zekri AR, Bahnassy AA, Mohamed WS, Alam El-Din HM, Shousha HI, Zayed N, Eldahshan DH, Abdel-Aziz AO. Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon. Virol J. 2013 Jul 1;10:218. doi: 10.1186/1743-422X-10-218.
Gamal Esmat, MD
Cairo University
Abdelrahman Zerki, PHD
Cairo University
Wahid Doss, MD
Cairo University
Maissa El Raziky, MD
Cairo University
First Submitted
December 25, 2012
First Posted
January 1, 2013
Study Start
January 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2016
Estimated (date passed)Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV
Contact the study team to confirm eligibility.
Gamal Sheha, MD
Cairo University
Tarneem Darwish, MSc.
Cairo University
samy zaki, MD
Cairo University
Magdi El-Serafy, MD
Cairo Universty
Fathalla Sedky, MD
Cairo University
Ahmed M Nasr, MD
Cairo University
Mostafa Gabr, MD
Cairo University
Ali kassem, MD
Cairo University
Ibrahim Metawea, MD
Cairo University
Noaman Al-Garem, MD
Cairo University
Hassan Hamdy, MD
Cairo University
Tawheed Mwafy, MD
Cairo University
Khalil A Khalil, MD
Cairo University
Magdy Atta, MD
Cairo University
Osama E Salem, MD
Cairo University
Mohamed A Afify, MD
Cairo University
Mohamed S Al-Shazly, MD
Cairo University
Hamdy Mahfouz, MD
Cairo University
Mustafa Gabr, MD
Cairo University
Monquez Motaea, MD
Cairo University
Hossam Abdel-Latif, MD
Cairo University
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 17, 2013
Record last verified: 2013-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: